According to The Fly, Berenberg Bank research analysts covered Blueprint Medicines (NASDAQ: BPMC) in a note distributed to investors on Wednesday. The company advised the company to “buy” its shares in the biotech company and gave it a “buy” rating. Recent events have led to the preparation of research papers on the company by more equity research analysts who have contributed to the company. In a research note published Tuesday, September 6, Oppenheimer raised its price target on Blueprint Medicines from $80.00 to $90.00 and rated the company as an “outperformer.” Blueprint Medicines was given a “buy” rating and a target price increase of $80.00 by Jefferies Financial Group in a research report released August 22. The study indicated that the company’s price target had been raised from $79.00 to $84.00. In addition, a rating was assigned to the company in this study. Stifel Nicolaus gave Blueprint Medicines a “buy” rating in a research report released Thursday, August 18.
Additionally, the brokerage firm increased its price target for the company from $93.00 to $100.00. A suggestion to “buy” the company was also included in the search. Blueprint Medicines was listed as a “Buy” in a research report published Wednesday, August 17, and Wainwright reduced its price target on the company from $100 to $80.00. The information was released along with the company’s announcement that it would lower its price target on Blueprint Medicines. A “buy” recommendation was made for the company in the search. In a research report released on Wednesday, August 3, Raymond James ultimately lowered his price target for Blueprint Medicines from $133.00 to $115.00 and gave the company a “Strong Buy” rating. Two equity research analysts recommended selling the stock; four suggested that investors maintain their current position; eight indicated that investors are buying stocks, and one suggested that investors are buying stocks with a strong emphasis. The company received a “moderate buy” recommendation from the investment community, and the average price target was set at $92.19. This data was taken from the Bloomberg website. BPMC shares started the day with a price of $70.74 per share.
Over the past year, the price of a bottle of Blueprint Medicine has fluctuated from a low of $43.46 to a high of $117.86. The price of the stock is estimated at $60.76 based on the simple moving average calculated over the last 200 days, and it is estimated at $63.89 based on the simple moving average calculated over the last 50 days. The company has a price-to-earnings ratio of -5.96, contributing to its market capitalization of $4.21 billion, and its beta value is 0.78. These two factors contribute to the market capitalization of the company. On August 2, shareholders of Blueprint Medicines (NASDAQ: BPMC) had access to the company’s latest quarterly earnings report. The biotech company reported earnings per share (EPS) for the quarter of $2.68, which was lower than market analysts had expected as they had forecast a profit of $2.23. Additionally, Blueprint Medicines’ net margin and return on equity were in the red. Net margin was -304.41% and return on equity was -458.90%. The company’s last fiscal quarter ended with actual sales of $36.55 million, which is below the average expectation of $37.61 million for sales during this period.
The company reported a loss of $1.86 per share for the same period in the prior year’s financial statements. Blueprint Medicines reported a 33.9% increase in sales last quarter compared to the prior year period. Equity research experts say Blueprint Medicines will likely lose 9.2 cents per share in earnings per share (EPS) for the current fiscal year. Separately, on August 4, Christopher K. Murray, senior vice president of the company, sold 2,500 shares of the company. Christopher K. Murray is the company’s Senior Vice President. The total amount of money made from the sale of shares was $151,100.00, which equals $60.44 for each share bought and sold. Following the successful completion of the transaction, the senior vice president will directly own 21,320 shares of the company. Based on the current share price, this stake is estimated to be approximately $1,288,580.80. Our transaction was detailed in a document distributed by the SEC and posted on this website, where it is now available for inspection. Separately, on August 4, 2,500 shares of the company were sold by Christopher K. Murray, senior vice president of the company.
This was cited as having taken place by the company in its report. The total amount of money made from the sale of shares was $151,100.00, which equals $60.44 for each share bought and sold. Following the successful completion of the transaction, the senior vice president will directly own 21,320 shares of the company. Based on the current share price, this stake is estimated to be approximately $1,288,580.80. Our transaction was detailed in a document distributed by the SEC and posted on this website, where it is now available for inspection. Additionally, on August 24, insider Debra Durso-Bumpus sold 5,000 shares of the company. She is part of the company’s management team. The stock was sold for a total of $375,550.00 and the price received for it, on average, was $75.11 per share. Following the successful completion of the transaction, the company insider now owns 40,836 shares of the company, with a total value of $3,067,191.96. This is the section where you can find the disclosure associated with the sale. Over the past ninety days, business insiders have sold 47,500 shares of the company, bringing in a total of $3,300,123 in proceeds from their trades. Business insiders own 42% of the company’s total shares.
A number of the company’s key shareholders have recently adjusted the way they now hold shares in their company. Brown Advisory Inc. increased the proportion of Blueprint Medicines it had invested in by 5.1% during the second quarter. Brown Advisory Inc. now owns a total of 960,269 shares issued by the biotechnology company, which is worth $48,503,000 thanks to the acquisition of 46,976 additional shares during the last fiscal quarter. Brown Advisory Inc.’s holdings of these shares are worth $48,503,000. During the second quarter, Captrust Financial Advisors increased the proportion of Blueprint Medicines in which it had invested capital by 5.4%. As a result, Captrust Financial Advisors now directly owns 17,074 shares held by the biotech company due to the purchase of 868 additional shares during the last fiscal quarter. These shares are worth a total of 862 thousand dollars. During the second quarter, Legal & General Group Plc increased the amount of Blueprint Medicines shares held by 2.5%. After buying in the last quarter, Legal & General Group Plc now owns 54,708 shares in the biotech sector, bringing those shares to $2,763,000.
This brings the total number of shares the company owns to a total of 54,708. Compared to its previous holdings, this translated into an increase of 1,344 shares for the company. During the second quarter of the fiscal year, ExodusPoint Capital Management LP invested an additional $858,000 in Blueprint Medicines to purchase a new investment in the company. During the second quarter, Walleye Capital LLC made a new investment in Blueprint Medicines with a payment of $264,000. Pharmaceuticals for blood disorders and tumors that have distinct genomic fingerprints are being developed by Blueprint Medications Corporation, which is a company specializing in the field of precision medicine. These pharmaceuticals are sold in local and international markets. AYVAKIT is administered to patients who have been diagnosed with systemic mastocytosis (MS) as well as gastrointestinal stromal tumors. BLU-263 is a powerful KIT inhibitor that can be taken orally and is used to treat patients who suffer from less advanced forms of mast cell disease and other types of mast cell disorders. Fisogatinib, a potent inhibitor that can be taken by mouth, is now used to treat patients diagnosed with hepatocellular carcinoma.